CLOs on the Move

Elastrin Therapeutics

www.elastrin.com

 
Elastrin Therapeutics is a South Carolina-based biotech developing novel therapies to reverse cardiovascular disease. Its underlying technology was developed by Dr. Naren Vyavahare during the last 20 years at Clemson University, in collaboration with Dr. Charles Rice.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Similar Companies

HONOUR

HONOUR is a global leader in chemistry-driven solutions, focusing on the pharmaceutical, electronics, and performance materials industries. The company emphasizes innovation and agility, supported by a strong scientific workforce. HONOUR specializes in Custom Synthesis and Contract Development and Manufacturing Organization (CDMO) services, offering a range of customizable chemicals and ingredients, including coupling reagents, excipients, and polymer monomers. The Research & Development team at HONOUR combines advanced chemistry and technology to create practical solutions tailored to the unique needs of its partners. The company values trust and integrity in its relationships, aiming to foster sustainable progress in collaboration with its clients. HONOUR serves a diverse clientele, including pharmaceutical companies and electronics manufacturers, providing them with expert R&D capabilities and customized chemical solutions.

Genome Quebec

Genome Quebec is a Montreal, QC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

InCarda Therapeutics

InCarda Therapeutics is a clinical stage drug delivery company pioneering a novel approach of treating cardiovascular diseases and conditions by the inhalation route.

Provident Clinical Research and Consulting

Provident Clinical Research & Consulting, Inc. is a Bloomington, IN-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Artizan Biosciences

Artizan Biosciences, Inc. is a biotechnology company with a mission to restore lives disrupted by inflammatory disease through innovation and advancement of microbiota-targeted therapies. We are leveraging our proprietary IgA-SEQ™ technology platform to distinguish disease-driving bacteria from the intestinal microbiota with the goal of developing new and potentially curative treatments.